Search

Your search keyword '"Cupelli, L."' showing total 234 results
Start Over Author "Cupelli, L."
234 results on '"Cupelli, L."'

2. P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP

Author

Fazio, F., primary, Passucci, M., additional, Lisi, C., additional, Micozzi, J., additional, Fianchi, L., additional, Di Landro, F., additional, Za, T., additional, Gumenyuk, S., additional, Ferraro, S., additional, Anaclerico, B., additional, De Padua, L., additional, Annibali, O., additional, Rago, A., additional, Piciocchi, A., additional, Bongarzoni, V., additional, Cupelli, L., additional, Mengarelli, A., additional, De Stefano, V., additional, Martelli, M., additional, and Petrucci, M.T., additional

Published
2023
Full Text
View/download PDF

4. List of Contributors

Author

Boudon, M., primary, Bynum, J., additional, Cupelli, L., additional, De Tommasi, L., additional, Ellis, K.A., additional, Good, N., additional, Greifenberg, T., additional, Kelly, D., additional, Klepal, M., additional, Kouramas, K., additional, L’Helguen, E., additional, Look, M., additional, Mancarella, P., additional, Martínez Ceseña, E.A., additional, Monti, A., additional, Mueller, D., additional, Pesch, D., additional, Ridouane, E.H., additional, Schumacher, M., additional, and Upton, C., additional

Published
2017
Full Text
View/download PDF

6. Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation

Author

Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, S., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Matera, R., Seripa, D., Codega, P., Bonizzoni, E., Specchia, G., Chiusolo P. (ORCID:0000-0002-1355-1587), Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, S., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Matera, R., Seripa, D., Codega, P., Bonizzoni, E., Specchia, G., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of the multiple day chemotherapy. While studies have shown effective prevention of CINV during the conditioning phase with NK1 receptor antagonist (NK1RA)-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT. Methods: This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin’s lymphoma. Eighty-one patients participated. Results: Response rates were 77.8% for complete response (no emesis and no rescue use), 72.8% for complete control (complete response and no more than mild nausea), 86.4% for no emesis, and 82.7% for no rescue use during the overall phase (duration of chemomobilization through 48 h after). NEPA was well tolerated with no treatment-related adverse events reported. Conclusion: NEPA, administered with a simplified every-other-day schedule, show to be very effective in preventing CINV in patients at high risk of CINV undergoing to chemomobilization of hematopoietic stem cells prior to ASCT.

Published
2022

7. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

Author

Bruzzese, A., primary, Derudas, D., additional, Galli, M., additional, Martino, E. A., additional, Rocco, S., additional, Conticello, C., additional, Califano, C., additional, Giuliani, N., additional, Mangicavalli, S., additional, Farina, G., additional, Lombardo, A., additional, Brunori, M., additional, Rossi, E., additional, Antonioli, E., additional, Ria, R., additional, Zambello, R., additional, Di Renzo, N., additional, Mele, G., additional, Marcacci, G., additional, Pietrantuono, G., additional, Palumbo, G., additional, Cascavilla, N., additional, Cerchione, C., additional, Belotti, A., additional, Criscuolo, C., additional, Uccello, G., additional, Curci, P., additional, Vigna, E., additional, Mendicino, F., additional, Iaccino, E., additional, Mimmi, S., additional, Botta, C., additional, Vincelli, D., additional, Sgherza, N., additional, Bonalumi, A., additional, Cupelli, L., additional, Stocchi, R., additional, Martino, M., additional, Ballanti, S., additional, Gangemi, D., additional, Gagliardi, A., additional, Gamberi, B., additional, Pompa, A., additional, Tripepi, G., additional, Frigeri, F., additional, Consoli, U., additional, Bringhen, S., additional, Zamagni, E., additional, Patriarca, F., additional, De Stefano, V., additional, Di Raimondo, F., additional, Palmieri, S., additional, Petrucci, M. T., additional, Offidani, M., additional, Musto, P., additional, Boccadoro, M., additional, Cavo, M., additional, Neri, A., additional, Morabito, F., additional, and Gentile, M., additional

Published
2022
Full Text
View/download PDF

8. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

Author

Fazio, F, Franceschini, L, Tomarchio, V, Rago, A, Garzia, Mg, Cupelli, L, Bongarzoni, V, Andriani, A, Gumenyuk, S, Tafuri, A, Siniscalchi, A, Piciocchi, A, De Fabritiis, P, De Rosa, L, Caravita di Toritto, T, Annibali, O, Cantonetti, M, and Petrucci, Mt

Subjects
multiple myeloma, immunotherapy, relapsed refractory, Settore MED/15
Abstract

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

Published
2021

14. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study

Author

Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, V., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Codega, P., Bonizzoni, E., Specchia, G., Chiusolo P. (ORCID:0000-0002-1355-1587), Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, V., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Codega, P., Bonizzoni, E., Specchia, G., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Despite the availability of several antiemetics, clinical findings show that control of chemotherapy-induced nausea and vomiting (CINV) continues to be a serious concern for hematological patients, mainly for those receiving multiple-day (MD) and high-dose (HD) chemotherapy (CT). For CINV prophylaxis, 5-hydroxytryptamine type-3 receptor antagonists (5HT3-RAs) and neurokinin 1 receptor antagonists (NK1-RAs) are usually administered together with dexamethasone, which may increase the risk of serious infections in patients undergoing myeloablative treatment. The rationale of this multicenter, open-label and phase IIa study was to explore the efficacy of multiple doses of NEPA (netupitant/palonosetron) given as an every-other-day regimen without dexamethasone in preventing CINV in patients with relapsed-refractory aggressive non-Hodgkin’s lymphoma (R/R-NHL), eligible for autologous stem cell transplantation (ASCT) and treated with MD-HD-CT. Seventy patients participated to the study. According to the adopted Fleming one-stage design, the primary endpoint of this study was achieved. The CR values were 87.1% (primary endpoint, overall phase: days 1–8), 88.6% (acute phase: days 1–6), and 98.6% (delayed phase: days 7–8), while complete control (CR with no more than mild nausea) was 85.7% (overall phase), 88.6% (acute phase), and 95.7% (delayed phase). Moderate and severe episodes of nausea were reported by less than 10% of patients in the overall phase and less than 5% in both the acute and delayed phases. Regarding safety, NEPA was well tolerated with only one adverse event (constipation) evaluated as possibly related to NEPA administration. In conclusion, our study demonstrated that multiple alternate dosing of NEPA without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting, with a good tolerability profile.

Published
2020

16. Disability among recipients of autologous or allogeneic haematopoietic stem cell transplant: a retrospective study from the Quality of Life Working Party of the Rome Tranplant Network: P1421

Author

Ciscato, C., Tendas, A., Dʼapolito, A., Mauroni, M. R., Pilozzi, V., Cacciaraichi, S., Viggiani, C., Mazza, P., Molinari, V., Purificato, K., Grigore, D., Rana, I., Mengarelli, A., Pignatelli, A., Cupelli, L., Anaclerico, B., Porrini, R., Annibali, O., Mirabile, M., Palumbo, G., Trenta, F., Tirindelli, M. C., Dentamaro, T., De fabritiis, P., and Arcese, W.

Published
2011

27. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, Capria, S, Mastronuzzi, A, Pagliara, D, Bernaschi, P, Amico, L, Carotti, A, Mencacci, A, Bruno, B, Costa, C, Passi, A, Ravizzola, G, Angelucci, E, Marchese, A, Pecile, P, Ventura, G, Fanin, R, Scarparo, C, Barbaro, A, Leotta, S, Marchese, Ae, Becchimanzi, C, Donnarumma, D, Tringali, S, Baldi, Mt, Scalone, R, Picardi, A, Arcese, W, Fontana, C, Giammarco, S, Spanu, T, Crocchiolo, R, Casari, E, Mussetti, A, Conte, E, Ensoli, F, Miragliotta, G, Marone, P, Arghittu, M, Greco, R, Forcina, A, Chichero, P, Di Bartolomeo, P, Fazii, P, Kroumova, V, Decembrino, N, Zecca, M, Pisapia, G, Palazzo, G, Lanino, E, Faraci, M, Castagnola, E, Bandettini, R, Pastano, R, Sammassimo, S, Passerini, R, Stefani, Pm, Gherlinzoni, F, Rigoli, R, Prezioso, L, Cambò, B, Calderaro, A, Carella, Am, Cascavilla, N, Labonia, Mt, Celeghini, I, Mordini, N, Piana, F, Vacca, A, Sanna, M, Podda, G, Corsetti, Mt, Rocchetti, A, Cilloni, D, De Gobbi, M, Bianco, O, Fagioli, F, Carraro, F, De Intinis, G, Severino, A, Proia, A, Parisi, G, Vallisa, D, Confalonieri, M, Russo, D, Malagola, M, Galieni, P, Falcioni, S, Travaglini, V, Raimondi, R, Borghero, C, Pavan, G, Prete, A, Belotti, T, Ambretti, S, Imola, M, Mianulli, Am, Pedna, Mf, Cesaro, S, Lo Cascio, G, Ferrari, A, Piedimonte, M, Santino, I, Calandrelli, M, Olivieri, A, Orecchioni, F, Mirabile, M, Centurioni, R, Gironacci, L, Caravelli, D, Gallo, S, De Filippi, M, Cupelli, L, Dentamaro, T, Falco, S, Eugenio, Os, Marotta, S, Risitano, A, Lula, D, Musto, P, Pietrantuono, G, Traficante, A, Cerchiara, E, Tirindelli, Mc, Dicuonzo, G, Chierichini, A, Anaclerico, B, and Placanica, P.

Published
2017

28. Homecare-based motor rehabilitation in musculoskeletal chronic graft versus host disease

Author

Tendas, A., Boschetto, C., Baraldi, L., Caiazza, E., Cupelli, L., Lentini, R., Trawinska, M., Palombi, M., Ales, M., Morino, L., Giovannini, M., Scaramucci, L., Cartoni, C., Dentamaro, T., Arcese, W., De Fabritiis, P., Niscola, P., and Mandelli, F.

Subjects
Palliative treatment -- Methods, Graft versus host reaction -- Development and progression -- Care and treatment -- Patient outcomes, Stem cells -- Transplantation, Medicine, Physical -- Usage -- Patient outcomes, Health
Abstract

Byline: A. Tendas, C. Boschetto, L. Baraldi, E. Caiazza, L. Cupelli, R. Lentini, M. Trawinska, M. Palombi, M. Ales, L. Morino, M. Giovannini, L. Scaramucci, C. Cartoni, T. Dentamaro, W. [...]

Published
2011

29. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., Olivieri A., Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., and Olivieri A.

Abstract

Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-3.13; P <.001) and auto-HSCT (2.43; 1.22-4.84; P =.01). Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.

Published
2017

31. Protection during haempoietic stem cell transplantation: a survey from the quality of life working party of the Rome Transplant Network

Author

Annibali, O, primary, Tendas, A, additional, Pignatelli, A, additional, Mauroni, R, additional, Carli, I, additional, Chierichini, A, additional, Tomarchio, V, additional, Cupelli, L, additional, Saltarelli, D, additional, Inzeo, A, additional, Surano, M, additional, Piedimonte, M, additional, Marchesi, F, additional, Sollazzo, F, additional, Conte, E, additional, Viggiani, C, additional, Di Piazza, F, additional, Tirindelli, M C, additional, and Arcese, W, additional

Published
2017
Full Text
View/download PDF

32. Allogeneic Transplant in Acute Myeloid Leukemia (AML) According to the Policy of the Rome Transplant Network (RTN): An Intention-to-Treat Analysis

Author

Arcese, W., Amadori, S., Cerretti, R., Cudillo, L., Angelis, G., Venditti, A., Buccisano, F., Cantonetti, M., Mangione, I., Andreani, M., Testi, M., Rapanotti, M. C., Fabritiis, P., Dentamaro, T., Cupelli, L., Tendas, A., Tirindelli, M. C., Annibali, O., Saltarelli, F., Mengarelli, A., Marchesi, F., Gumenyuk, S., Chierichini, A., Anaclerico, B., agostino tafuri, Montefusco, E., Ferrari, A., Naso, V., Di Piazza, F., and Picardi, A.

Published
2015

33. Controversies on Antibiotic Lock Technique Duration Experience with a 3-Day Course for Hematological Patients

Author

Tendas, A, Cudillo, L, Niscola, P, Cupelli, L, Picardi, A, Spagnoli, A, Scaramucci, L, Giovannini, M, Ales, M, Mirabile, M, Bove, F, Falco, S, Dentamaro, T, and Fabritiis, P

Subjects
Microbiology (medical), medicine.medical_specialty, Catheters, Time Factors, Epidemiology, Bacteremia, Vancomycin, Staphylococcus epidermidis, medicine, Humans, Settore MED/05 - Patologia Clinica, Catheter-Related Infections, Teicoplanin, Amikacin, Catheters, Indwelling, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Staphylococcal Infections, Staphylococcus haemolyticus, Antibiotic lock, Duration (project management), business.industry, Surgery, Infectious Diseases, Indwelling, Emergency medicine, business, Settore MED/15 - Malattie del Sangue
Published
2011
Full Text
View/download PDF

34. High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant

Author

Bruno, A, De Meis, I, Cantoni, F, Siniscalchi, A, Velotta, V, Tendas, A, Cupelli, L, Dentamaro, T, Piccioni, D, DEL POETA, G, Ballatore, G, Tamburini, A, Suppo, G, Del Proposto, G, Adorno, G, Isacchi, G, Arcese, W, Amadori, S, Perrotti, A, DE FABRITIIS, P, and Caravita, T

Subjects
Settore MED/15 - Malattie del Sangue
Published
2012

35. [Membranous glomerulonephritis secondary to allogeneic stem cell transplant: review of the literature]

Author

Vischini G, Niscola P, Ferrannini M, Cupelli L, Tendas A, Scaramucci L, Giovannini M, Dentamaro T, Paolo de Fabritiis, and Palumbo R

Subjects
Risk Factors, Humans, Settore MED/15, Glomerulonephritis, Membranous, Stem Cell Transplantation
Abstract

Renal injury associated with hematopoietic stem cell transplant (HSCT) may be related to a combination of factors. Chronic graft-versus-host disease (cGVHD) is the most common complication of allogeneic HSCT. Although the kidneys are not considered the primary target organs for GVHD, chronic impairment of renal function may occur in 20% to 60% of HSCT patients. Membranous glomerulonephritis (MG) is the most frequent renal complication observed in patients who develop nephrotic syndrome after allogeneic HSCT. In this setting, the pathogenesis of MG is not clearly understood and the most appropriate treatment approach has not been established. In order to summarize the current knowledge on this issue, a review of the pertinent literature has been performed. The available data on MG diagnosed in patients submitted to allogeneic HSCT were identified using the MEDLINE database (last accessed: Jan 30, 2012). Fifty-nine patients with allogeneic HSCT-related MG with a median age of 43 years were identified. MG occurred at a median time of 17 months after allogeneic HSCT. A history of acute or concomitant clinically apparent cGVHD was present in 69% and 31% of cases, respectively. cGVHD, nonmyeloablative conditioning regimens, immunosuppression withdrawal, and the use of peripheral blood stem cell grafts were identified as risk factors. Among the 53 patients with available outcome data, complete remission, partial response, and inefficacy of treatment were recorded in 65%, 22% and 13% of cases, respectively. MG after allogeneic HSCT seems to be etiologically related to subclinical or overt cGVHD, which flares up after discontinuation of immunosuppression. The available measures can induce sustained long-term remission in about two-thirds of affected patients.

Published
2012

39. The potential application of the allogeneic transplant according to a widespread donor search policy: an intention-to-treat analysis from the Rome Transplant Network

Author

Picardi, A, DE FABRITIIS, P, Dentamaro, T, De Rossi, G, Caniglia, M, Petti, M, Mengarelli, A, Annino, L, Chierichini, A, Monarca, B, Ferrari, A, Avvisati, G, Tirindelli, M, Mangione, I, Pinto, R, Montefusco, E, Annibali, O, Cupelli, L, Cudillo, L, Cerretti, R, De Angelis, G, Giannotti, F, Di Veroli, A, Provenzano, I, Mirabile, M, and Arcese, W

Subjects
Settore MED/15 - Malattie del Sangue
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results